Crcm LP bought a new position in shares of Burning Rock Biotech Limited (NASDAQ:BNR - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 325,969 shares of the company's stock, valued at approximately $2,200,000. Burning Rock Biotech makes up 0.9% of Crcm LP's investment portfolio, making the stock its 5th largest position. Crcm LP owned approximately 3.18% of Burning Rock Biotech at the end of the most recent reporting period.
Burning Rock Biotech Stock Up 9.4 %
NASDAQ BNR traded up $0.51 during trading hours on Friday, hitting $5.96. The company's stock had a trading volume of 4,509 shares, compared to its average volume of 13,628. The stock has a fifty day moving average of $6.54 and a 200 day moving average of $5.26. Burning Rock Biotech Limited has a twelve month low of $2.62 and a twelve month high of $8.99. The firm has a market capitalization of $61.05 million, a P/E ratio of -1.99 and a beta of 0.55.
About Burning Rock Biotech
(
Free Report)
Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.
Featured Articles
Before you consider Burning Rock Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Burning Rock Biotech wasn't on the list.
While Burning Rock Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
